Abstract: Apparatus for endoscopically retracting tissue, the apparatus comprising a sleeve adapted to be slid over the exterior of an endoscope; a balloon movably mounted to the sleeve; and at least one connector extending from the balloon and configured to be secured to tissue which is to be retracted; wherein the balloon is configured to be moved relative to the sleeve in order to retract the tissue.

Abstract: Present invention relates to development of compound of formula (I) for treatment of Cryopyrin Associated Periodic Syndromes (CAPS). Specifically, the present invention provides a NLRP3 inhibitors or its pharmaceutically acceptable salt for treatment of Cryopyrin Associated Periodic Syndromes (CAPS). Invention also relates to the pharmaceutical composition comprising compound of formula (I) or its pharmaceutically acceptable salts for treatment of Cryopyrin Associated Periodic Syndromes (CAPS).

Abstract: Apparatus comprising: a sleeve adapted to be slid over the exterior of an endoscope; a proximal balloon secured to the sleeve; an inflation/deflation tube carried by the sleeve and in fluid communication with the interior of the proximal balloon; a push tube slidably mounted to the sleeve; and a distal balloon secured to the distal end of the push tube, the interior of the distal balloon being in fluid communication with the push tube, wherein the distal balloon is capable of assuming a deflated condition and an inflated condition, and further wherein when the distal balloon is in its deflated condition, an axial opening extends therethrough, the axial opening being sized to receive the endoscope therein, and when the distal balloon is in its inflated condition, the axial opening is closed down.

Abstract: A system and method for digital-representation-based flight path planning for object imaging is disclosed. An example embodiment is configured to: obtain a digital representation of an object; retrieve a dataset of image acquisition configuration parameters; extract a surface contour of the object from the digital representation of the object; generate a bounding polygon adjacent to the surface contour of the object, the bounding polygon being set-off from the surface contour of the object based on a configuration defined in the image acquisition configuration parameters; generate a configurable quantity of waypoints at configurable intervals along the bounding polygon; and generate an Image Acquisition Plan (IAP) from the waypoints, the IAP including, for each waypoint, a waypoint position, control instructions, and imaging instructions.

Abstract: An endoscopic tissue snare system comprising: a sleeve adapted to be slid over the exterior of an endoscope; a pair of push tubes slidably mounted to the sleeve, each of the push tubes comprising a distal opening and a proximal opening; a distal balloon secured to the distal ends of the pair of push tubes; and a snare comprising a pair of free ends and an intermediate portion disposed between the pair of free ends, wherein the snare extends into the proximal opening of one push tube, up the length of the push tube, out the distal opening of that push tube, across the face of the distal balloon, into the distal opening of the other push tube, down the length of that push tube, and out the proximal opening of that push tube.

Abstract: A resource conservation system, including a determination processor may be provided. The determination processor may identify a characterization output that characterizes a plurality of data structures. The characterization output may be based on plurality of inputs. The inputs may be processed through a plurality, or cascade, of artificial intelligence models both in sequence and in parallel. A numerical value may be identified for each data structure. The value may identify a degree of certainty that the determination processor accurately characterized each data structure. When the degree is above a threshold, the determination processor may identify a subset of inputs that most contributed to the characterization output. The determination processor may execute an equation to identify a subset of inputs that most contributed to the output. The equation may involve inputs and/or outputs of each of the cascade of models. Identified inputs may be ranked based on contribution to the outcome.

Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses die sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.

Abstract: Apparatus for endoscopically retracting tissue, the apparatus comprising a sleeve adapted to be slid over the exterior of an endoscope; a balloon movably mounted to the sleeve; and at least one connector extending from the balloon and configured to be secured to tissue which is to be retracted; wherein the balloon is configured to be moved relative to the sleeve in order to retract the tissue.

Abstract: Apparatus for endoscopically retracting tissue, the apparatus comprising a sleeve adapted to be slid over the exterior of an endoscope; a balloon movably mounted to the sleeve; and at least one connector extending from the balloon and configured to be secured to tissue which is to be retracted; wherein the balloon is configured to be moved relative to the sleeve in order to retract the tissue.

Abstract: A resource conservation system, including a determination processor may be provided. The determination processor may identify a characterization output that characterizes a plurality of data structures. The characterization output may be based on plurality of inputs. The inputs may be processed through a plurality, or cascade, of artificial intelligence models both in sequence and in parallel. A numerical value may be identified for each data structure. The value may identify a degree of certainty that the determination processor accurately characterized each data structure. When the degree is above a threshold, the determination processor may identify a subset of inputs that most contributed to the characterization output. The determination processor may execute an equation to identify a subset of inputs that most contributed to the output. The equation may involve inputs and/or outputs of each of the cascade of models. Identified inputs may be ranked based on contribution to the outcome.

Abstract: A flow diverter is disclosed. The flow diverter can be removably securable to a medical device. The flow diverter can have a body and a cavity. When the body is removably secured to the medical device and when a flow of gas flows from the medical device into the cavity, the flow of gas can be divertible from a first direction to a second direction, and/or when the body is removably secured to the medical device and when the flow of gas flows from the medical device into the cavity, the flow of gas can be divertible out of the cavity.

Abstract: A system is disclosed that can have a first device and a second device. The first device can have a tube, a deflectable section, and a camera. The second device can have a first tube. A stabilizer can be advanceable from the first tube. The second device can have a second tube. A third tube can be advanceable from the second tube. The first device can be an endoscope. The first device can be attachable to the second device via a connector.

Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.

Abstract: A resource conservation system, including a determination processor may be provided. The determination processor may identify a characterization output that characterizes a plurality of data structures. The characterization output may be based on plurality of inputs. The inputs may be processed through a plurality, or cascade, of artificial intelligence models both in sequence and in parallel. A numerical value may be identified for each data structure. The value may identify a degree of certainty that the determination processor accurately characterized each data structure. When the degree is above a threshold, the determination processor may identify a subset of inputs that most contributed to the characterization output. The determination processor may execute an equation to identify a subset of inputs that most contributed to the output. The equation may involve inputs and/or outputs of each of the cascade of models. Identified inputs may be ranked based on contribution to the outcome.

Abstract: An endoscopic tissue retraction system comprising: an element configured to be movably mounted to an endoscope; and a connector configured to be secured to the element and to the tissue which is to be retracted.

Abstract: There is provided a composition suitable for oral transmucosal administration (sublingual) comprising dexmedetomidine. The composition is useful for the treatment of sleep disorders such as insomnia and capable of providing sleep on demand. The composition comprises an effective amount of dexmedetomidine or pharmaceutically acceptable salts thereof, solvates thereof, or derivatives thereof, formulated for delivery of dexmedetomidine across a subject's oral mucosa.

Abstract: The present disclosure relates to uses of compounds of formula (I) in treating or preventing variety of diseases, or conditions in a subject particularly hepatobiliary disease, gastrointestinal diseases associated with hepatobiliary disease and/or eosinophilic diseases using therapeutic effective amounts of compound of general formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein the variables R1, R2, Ar, X, Z and W have the meaning as described herein.

Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.

Abstract: A system and method for quantitative image quality assessment for photogrammetry are disclosed.

Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.